Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Dalle · SciRah

Researcher profile · Semantic Scholar

S. Dalle

Share profile

S. Dalle — researcher profile on SciRah

h-index: 68
Works: 413
Citations: 22K

Most-cited papers

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
H. Tawbi, D. Schadendorf, E. Lipson, P. Ascierto +18 more
2022New England Journal of Medicine1,514 citations Open access
Semantic Scholar
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
A. Eggermont, C. Blank, M. Mandalà, G. Long +27 more
2021The Lancet Oncology327 citations Open access
Semantic Scholar
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
A. Stratigos, A. Sekulic, K. Peris, O. Bechter +34 more
2021The Lancet Oncology237 citations Open access
Semantic Scholar
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
J. Larkin, M. Del Vecchio, M. Mandalà, H. Gogas +27 more
2023Clinical Cancer Research171 citations Open access
Semantic Scholar
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
P. Ascierto, E. Lipson, R. Dummer, J. Larkin +18 more
2023Journal of Clinical Oncology144 citations Open access
Semantic Scholar
Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation
Alexandra Lainé, Ossama Labiad, H. Hernández-Vargas, S. This +7 more
2021Nature Communications144 citations Open access
Semantic Scholar
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
J. Weber, D. Schadendorf, M. Del Vecchio, J. Larkin +32 more
2022Journal of Clinical Oncology140 citations Open access
Semantic Scholar
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.
A. Eggermont, M. Kicinski, C. Blank, M. Mandalà +26 more
2022NEJM Evidence134 citations
Semantic Scholar
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
E. Lipson, H. Tawbi, D. Schadendorf, P. Ascierto +15 more
2021115 citations
Semantic Scholar
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data
S. Horwitz, J. Scarisbrick, R. Dummer, S. Whittaker +22 more
2021Blood Advances109 citations Open access
Semantic Scholar
ZEB1 transcription factor promotes immune escape in melanoma
Maud Plaschka, Valentin Benboubker, Maxime Grimont, Justine Berthet +14 more
2022Journal for ImmunoTherapy of Cancer90 citations Open access
Semantic Scholar
EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment
Yaqi Tang, S. Durand, S. Dalle, J. Caramel
2020Cancers88 citations Open access
Semantic Scholar
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort
L. Hountondji, Christophe Ferreira De Matos, F. Lebossé, X. Quantin +16 more
2023JHEP Reports84 citations Open access
Semantic Scholar
Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
M. Espi, C. Teuma, E. Novel-Catin, D. Maillet +4 more
2021European Journal of Cancer67 citations Open access
Semantic Scholar
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
A. de Masson, M. Beylot-Barry, C. Ram-Wolff, J. Mear +49 more
2023The Lancet62 citations Open access
Semantic Scholar
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
A. Bottomley, C. Coens, J. Mierzynska, C. Blank +30 more
2021The Lancet Oncology58 citations Open access
Semantic Scholar
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
O. Kennedy, M. Kicinski, S. Valpione, S. Gandini +27 more
2022European Journal of Cancer50 citations Open access
Semantic Scholar
PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study.
J. Delyon, L. Biard, M. Renaud, M. Resche-Rigon +11 more
2022The Lancet Oncology47 citations Open access
Semantic Scholar
Ocular Inflammation Induced by Immune Checkpoint Inhibitors
Florence Chaudot, P. Sève, A. Rousseau, A. Maria +13 more
2022Journal of Clinical Medicine44 citations Open access
Semantic Scholar
Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma
Valentin Benboubker, F. Boivin, S. Dalle, J. Caramel
2022Frontiers in Immunology40 citations Open access
Semantic Scholar
Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy.
C. Mandel-Brehm, S. Vazquez, Christopher S. Liverman, Mickie H. Cheng +23 more
2022Diabetes37 citations Open access
Semantic Scholar
Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)
G. Long, F. Hodi, E. Lipson, D. Schadendorf +16 more
2022Journal of Clinical Oncology35 citations
Semantic Scholar
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
G. Long, C. Robert, M. Butler, F. Couture +14 more
2021Clinical Cancer Research35 citations Open access
Semantic Scholar
Primary cutaneous peripheral T‐cell lymphomas with a T‐follicular helper phenotype: an integrative clinical, pathological and molecular case series study
Luo-Jun Wang, D. Rocas, S. Dalle, N. Sako +14 more
2022British Journal of Dermatology33 citations Open access
Semantic Scholar
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study
L. Plaçais, S. Dalle, O. Dereure, S. Trabelsi +18 more
2022Annals of the Rheumatic Diseases31 citations Open access
Semantic Scholar
Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)
G. Long, D. Schadendorf, M. Del Vecchio, J. Larkin +29 more
2021Clinical Trials31 citations
Semantic Scholar
Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma
N. Leupin, P. Zinzani, F. Morschhauser, S. Dalle +26 more
2021Cancer30 citations
Semantic Scholar
Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T‐cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop *
W. Kempf, T. Petrella, R. Willemze, P. Jansen +29 more
2022British Journal of Dermatology29 citations
Semantic Scholar
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
J. Larkin, J. Weber, M. Del Vecchio, H. Gogas +23 more
2022European Journal of Cancer28 citations Open access
Semantic Scholar
Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
Mathilde Peiffert, C. Cugnet-Anceau, S. Dalle, K. Chikh +5 more
2021Cancers26 citations Open access
Semantic Scholar
Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis
P. Courand, Mathilde Berger, M. Amini-Adle, A. Bouali +5 more
2020Cancer Medicine22 citations Open access
Semantic Scholar
Health-related quality of life in cancer immunotherapy: a systematic perspective, using causal loop diagrams
E. Beaulieu, A. Spanjaart, Ashley Roes, B. Rachet +4 more
2022Quality of Life Research20 citations Open access
Semantic Scholar
Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes
Charline Lafayolle de la Bruyère, P. Souquet, S. Dalle, P. Corbaux +8 more
2021Cancers20 citations Open access
Semantic Scholar
Deciphering the spectrum of cutaneous lymphomas expressing TFH markers
M. Donzel, A. Trécourt, B. Balme, O. Harou +8 more
2023Scientific Reports16 citations Open access
Semantic Scholar
Dermatoscopic and clinical features of congenital or congenital-type nail matrix nevi: A multicenter prospective cohort study by the International Dermoscopy Society
F. Pham, A. Boespflug, G. Duru, A. Phan +39 more
2022Journal of American Academy of Dermatology16 citations Open access
Semantic Scholar
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.
H. Tawbi, F. Hodi, E. Lipson, D. Schadendorf +15 more
2023Journal of Clinical Oncology15 citations
Semantic Scholar
Atypical extensive lupus tumidus‐like eruption as an early presentation of VEXAS syndrome
E. Ribereau-Gayon, M. Heiblig, E. Bourbon, P. Sujobert +6 more
2021International Journal of Dermatology15 citations
Semantic Scholar
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
S. Dalle, L. Mortier, P. Corrie, M. Lotem +15 more
2021BMC Cancer14 citations Open access
Semantic Scholar
Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group
C. Bergqvist, M. Beylot-Barry, C. Ram-Wolff, B. Vergier +15 more
2021Clincal and Experimental Dermatology14 citations
Semantic Scholar
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
M. Mandalà, J. Larkin, P. Ascierto, M. Del Vecchio +21 more
2021Journal for ImmunoTherapy of Cancer13 citations Open access
Semantic Scholar
Onset of acquired haemophilia A after omalizumab treatment in severe bullous pemphigoid - a report on two cases successfully treated with mycophenolate mofetil.
M. Mangin, A. Lienhart, A. Gouraud, S. Roux +5 more
2021Annales de dermatologie et de vénéréologie12 citations
Semantic Scholar
Quality‐of‐life assessment in French patients with metastatic melanoma in real life
M. Kandel, S. Dalle, A. Bardet, C. Allayous +23 more
2020Cancer12 citations Open access
Semantic Scholar
Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study
M. Maugeais, J. Péron, S. Dalle, A. Boespflug +8 more
2022Biomedicines11 citations Open access
Semantic Scholar
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.
M. Girod, S. Dalle, L. Mortier, S. Dalac +14 more
2022JCO Precision Oncology11 citations
Semantic Scholar
Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab
F. Pham, Samy Belkaid, D. Maillet, C. Confavreux +2 more
2022Biomedicines11 citations Open access
Semantic Scholar
Clinical Features, Histological Characteristics, and Disease Outcomes of Mycosis Fungoides in Children and Adolescents: A Nationwide Multicentre Cohort of 46 Patients
A. Welfringer-Morin, M. Barroil, S. Fraitag, V. Szablewski +24 more
2022Dermatology11 citations Open access
Semantic Scholar
Clinicopathological and molecular analysis of cutaneous leiomyosarcoma: A retrospective multicenter study of 79 cases.
Camille Planet, S. Dalle, O. Dereure, P. Stoebner +12 more
2022Journal of American Academy of Dermatology10 citations Open access
Semantic Scholar
Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma
Marie-Alix Mangin, A. Boespflug, Delphine Maucort Boulch, C. Vacheron +3 more
2021Cancer Medicine10 citations Open access
Semantic Scholar
Late-onset adverse events under anti-PD1 therapy in melanoma patients: an observational study from MELBASE, a nationwide prospective cohort.
C. Carlet, S. Dalle, M. Leccia, L. Mortier +15 more
2021Journal of American Academy of Dermatology10 citations Open access
Semantic Scholar
Adipocyte extracellular vesicles decrease p16INK4A in melanoma: an additional link between obesity and cancer.
I. Lazar, E. Clement, L. Carrié, D. Estève +8 more
2022Journal of Investigative Dermatology9 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Grob×16
Invite
J. Grob — researcher profile on SciRah
P. Ascierto×14
Invite
P. Ascierto — researcher profile on SciRah
G. Long×13
Invite
G. Long — researcher profile on SciRah
D. Schadendorf×11
Invite
D. Schadendorf — researcher profile on SciRah

×11

Invite

V. Atkinson — researcher profile on SciRah

Invite

H. Gogas — researcher profile on SciRah

Invite

A. Arance — researcher profile on SciRah

Invite

R. Gutzmer — researcher profile on SciRah

Invite

J. Larkin — researcher profile on SciRah

Invite

M. Mandalà — researcher profile on SciRah

Invite

M. Carlino — researcher profile on SciRah

A. D. di Giacomo×7

Invite

A. D. di Giacomo — researcher profile on SciRah